• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Florida Cancer Specialists Researcher First-Authored SABCS Breast Cancer Study

Article

A member of the clinical research team at Florida Cancer Specialists & Research Institute is to be a first author for a breast cancer study to be presented at San Antonio Breast Cancer Symposium.

Fort Myers, Florida — Medical oncologist Manish R. Patel, MD, a member of the clinical research team at Florida Cancer Specialists & Research Institute (FCS), served as the first author of a study examining dose escalation of an oral complete estrogen receptor antagonist/selective ER degrader in cases of advanced and/or metastatic estrogen receptor-positive, HER2-negative breast cancer.

Entitled, “Preliminary data from a phase I/II, multicenter, dose escalation study of OP-1250, an oral CERAN/SERD, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer,” the study was shared at the San Antonio Breast Cancer Symposium held Dec. 7-12, 2021.

While still ongoing, the study’s analysis indicates an evolution in the standard of care, to include complete estrogen receptor antagonists.

Learn more.

Related Videos
Joshua K. Sabari, MD< NYU Langone Perlmutter Cancer Center
dr marisa mcginley
Leslie Busby, MD, Rocky Mountain Cancer Centers
Camilla Levister
dr daniel ontaneda
Sudipto Mukherjee, MD, PhD, MPH, hematology and medical oncology, Cleveland Clinic
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
Sudipto Mukherjee, MD, PhD, MPH, hematology and medical oncology, Cleveland Clinic
Camilla Levister
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.